Merck Scraps Keytruda Trial for Prostate Cancer After Dismal Interim Data

0
351
Merck & Co Inc. said it was discontinuing a late-stage trial of its blockbuster immunotherapy Keytruda in some prostate cancer patients after interim data showed it was unlikely to meet the study’s main goals; the therapy did not extend survival or help extend the time a patient lives without the disease worsening.
[Reuters]
Press Release